Skip to main content

Table 1 Patients’ characteristics

From: TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

Patient number 101
Median age (years) 60
Histological subtype
 Serous 79 (78, 3%)
 Endometrioid 7 (7%)
 Mucinous 2 (1, 9%)
 Clear cell 2 (1, 9%)
 Mixed 3 (2, 9%)
 Other/not specifed 8 (8%)
Grading
 G1 0
 G2 7 (7%)
 G3 94 (93%)
Staging (FIGO)
 IC 1 (0, 9%)
 IIA 4 (3, 9%)
 IIB 7 (7%)
 IIIA 4 (3, 9%)
 IIIB 8 (8%)
 IIIC 56 (55, 5%)
 IV 21 (20, 8%)
PFI
 < 6 months 65 (64, 4%)
 ≥ 6 months 36 (35, 6%)
Number of previous chemoterapies
 1 82 (87, 3%)
 2 10 (10, 6%)
 ≥ 3 2 (2, 1%)
PLD-based regimen
 PLD monotherapy 54 (53, 4%)
 Carbo-PLD 30 (29, 7%)
 Trabe-PLD 17 (16, 9%)
CA-125 mean value (UI/mL)
 Pre-PLD treatment 1142
 Post-PLD treatment 1493
BRCA status
 BRCA 1–2 mutation 11 (10, 9%)
 BRCA 1–2 wild-type 12 (11, 9%)
 VUS/HRD 6 (5, 9%)
 Unknown 72 (71, 3%)
  1. FIGO International Federation of Gynaecology and Obstretics, PFI Platinum Free Interval from first platinum-based therapy, PLD Pegylated Liposomal Doxorubicin, Carbo Carboplatin, Trabe Trabectidin, CA-125 Cancer Antigen 125